Baby Detect : Genomic Newborn Screening

• ClinicalTrials.gov Identifier: NCT05687474
• Recruitment Status: Recruiting
• First Posted: January 18, 2023
• Last Update Posted: April 24, 2024
• Sponsor: Centre Hospitalier Universitaire de Liege
• Collaborators: Centre Hospitalier Régional de la Citadelle; University of Liege; Sanofi; Orchard Therapeutics; Takeda; Zentech-Lacar Company; Leon Fredericq Foundation
• Information provided by (Responsible Party): Laurent Servais, Centre Hospitalier Universitaire de Liege

Tracking Information

• First Submitted Date: December 28, 2022
• First Posted Date: January 18, 2023
• Last Update Posted Date: April 24, 2024
• Actual Study Start Date: September 1, 2022
• Estimated Primary Completion Date: August 31, 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 24, 2023)

• Acceptability [ Time Frame: through study completion, an average of 1 year ]
  The percentage of parents accepting the proposed screening in comparison with the number of mothers approached for consent
• Feasibility - timing [ Time Frame: through study completion, an average of 1 year ]
  The Turn-around time for the different mutations that are screened
• Feasibility - reliability [ Time Frame: through study completion, an average of 1 year ]
  The percentage of false positives and the predicted value for each test The estimation of the false negatives through collaboration with physicians treating the different diseases.

Original Primary Outcome Measures (submitted: January 13, 2023)

• Acceptability [ Time Frame: 1 year, year 1, 2, 3 ]
  The percentage of parents accepting the proposed screening in comparison with the number of mothers approached for consent
• Feasability - timing [ Time Frame: 1 year, year 1, 2, 3 ]
  The Turn-around time for the different mutations that are screened
• Feasabilty - reliability [ Time Frame: 1 year, year 1, 2, 3 ]
  The percentage of false positives and the predicted value for each test The estimation of the false negatives through collaboration with physicians treating the different diseases.

Current Secondary Outcome Measures (submitted: January 24, 2023)

• Consequence of NBS on early treatment access - timing [ Time Frame: through study completion, an average of 1 year ]
  The time passed between the birth of diagnostic-positive newborns to the initiation of their treatment
• Consequence of NBS on early treatment access - frequency [ Time Frame: through study completion, an average of 1 year ]
  The number of patients offered early treatment
• To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants. [ Time Frame: through study completion, an average of 1 year ]
  The number of new mutations implemented yearly in the NBS.

Original Secondary Outcome Measures (submitted: January 13, 2023)

• Consequence of NBS on early treatment access - timing [ Time Frame: 1 year, year 1, 2, 3 ]
  The time passed between the birth of diagnostic-positive newborns to the initiation of their treatment
• Consequence of NBS on early treatment access - frequency [ Time Frame: 1 year, year 1, 2, 3 ]
  The number of patients offered early treatment
• To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants. [ Time Frame: 1 year, year 1, 2, 3 ]
  The number of new mutations implemented yearly in the NBS.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Baby Detect : Genomic Newborn Screening
• Official Title: Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect

Brief Summary

Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the early start of transformative treatment will help avoid severe disabilities and increase the quality of life.

Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes. The list of diseases has been established in close collaboration with the Paediatricians of the University Hospital in Liege. The investigators use dedicated dried blood spots collected between the first day and 28 days of life of babies, after a consent sign by parents.

Detailed Description

Every year, thousands of children around the world are born with rare genetic diseases leading to death or lifelong disability. With technological advancements in the field of genetics and medicine, the rate of introduction of treatments for these rare conditions has grown remarkably.

However, timing is of great importance for medication administration. The benefit that can be measured in a patient who has already suffered from a long irreversible degenerative disorder is small and, sometimes, it hardly justifies the cost and the burden of the treatment. Early diagnosis is, thus, of primary importance both to obtain the best effect of the innovative medications and to accelerate their development.

The investigators are pioneered in the field of genetic newborn screening (NBS) in rare diseases by funding, designing, and leading an innovative genetic NBS program initiated in March 2018 in Southern Belgium for Spinal Muscular Atrophy (SMA) that allowed, so far, for 11 children to be detected and treated early and avoid the terrible fate of the disease. The program was disseminated in 17 countries and included public dissemination and health-economic analysis since the very beginning [1]. (www.facebook.com/sunmayariseonsma).

Drawing upon our experience with SMA screening, the investigators have designed a project to screen up to 40,000 newborns/year progressively in 3 years for virtually all the rare diseases that can benefit from treatment or a pre-symptomatic clinical trial.

The methodology of Baby Detect includes sequencing of target genes on dried blood spots collected from the NBS cards in a timely and cost-efficient manner, and its high dynamicity allows for any newly treatable rare disease to be included in its scheme in no longer than 6 months.

Baby Detect, as a multidisciplinary newborn screening program, involves expertise in areas from genetics and medicine to laboratory studies, computer science, Data Protection, Ethics, and health economy. It will constitute the proof of concept that is needed before moving to a whole region-scale population.

• Study Type: Observational
• Study Design: Observational Model: Cohort; Time Perspective: Prospective
• Target Follow-Up Duration: Not Provided

Biospecimen

Retention:   Samples With DNA

Description:

4 drops of dried blood on a blotter.

• Sampling Method: Non-Probability Sample
• Study Population: Newborns whose mothers and/or the second-parents meet the inclusion criteria and have provided their consent to take part in the study

Condition

• Congenital Adrenal Hyperplasia
• Familial Hyperinsulinemic Hypoglycemia 1
• Phosphoglucomutase 1 Deficiency
• Maturity Onset Diabetes of the Young
• Cystic Fibrosis
• Hypophosphatasia, Infantile
• Congenital Hypothyroidism
• Deficit in Anterior Pituitary Function and Variable Immunodeficiency
• Pituitary Hormone Deficiency, Combined
• Diamond Blackfan Anemia
• Wiskott-Aldrich Syndrome
• Fanconi Anemia
• Hemophilia A
• Hemophilia B
• Glucose 6 Phosphate Dehydrogenase Deficiency
• Alpha-Thalassemia
• Sickle Cell Disease
• Shwachman-Diamond Syndrome
• Alpha 1-Antitrypsin Deficiency
• Inflammatory Bowel Disease 25, Autosomal Recessive
• Wilson Disease
• Progressive Familial Intrahepatic Cholestasis
• Crigler-Najjar Syndrome
• Familial Chylomicronemia
• Lysosomal Acid Lipase Deficiency
• Familial Hemophagocytic Lymphocytosis
• Griscelli Syndrome
• Chediak-Higashi Syndrome
• Severe Congenital Neutropenia
• Severe Combined Immune Deficiency
• Chronic Granulomatous Disease
• Menkes Disease
• Adrenoleukodystrophy
• Smith-Lemli-Opitz Syndrome
• Ataxia With Vitamin E Deficiency
• Thiamine Metabolism Dysfunction Syndrome 5 (Episodic Encephalopathy Type)
• Thiamine Metabolism Dysfunction Syndrome 4 (Bilateral Striatal Degeneration and Progressive Polyneuropathy Type)
• Thiamine-Responsive Megaloblastic Anemia
• Thiamine Metabolism Dysfunction Syndrome 2
• Deficiency of GOT2
• Cerebral Folate Transport Deficiency
• Segawa Syndrome, Autosomal Recessive
• Congenital Myasthenic Syndrome
• Metachromatic Leukodystrophy
• Sepiapterin Reductase Deficiency
• Dopamine Beta Hydroxylase Deficiency
• Glut1 Deficiency Syndrome
• Late-Infantile Neuronal Ceroid Lipofuscinosis
• Aromatic L-amino Acid Decarboxylase Deficiency
• Charcot-Marie-Tooth Disease, Type 6C
• Hereditary Hyperekplexia
• Brain Dopamine-Serotonin Vesicular Transport Disease
• Very Long Chain Hydroxy Acyl Dehydrogenase Deficiency
• Tyrosinemia, Type I
• Disaccharide Intolerance I
• Beta Ketothiolase Deficiency
• Phosphoglycerate Dehydrogenase Deficiency
• Succinyl-Coa:3-Ketoacid Coa-Transferase Deficiency
• Pyridoxine-5'-Phosphate Oxidase Deficiency
• Pyridoxine-Dependent Epilepsy
• Propionic Acidemia
• Pompe Disease
• Phenylalanine Hydroxylase Deficiency
• Ornithine Transcarbamylase Deficiency
• N Acetyl Glutamate Synthetase Deficiency
• Riboflavin Deficiency
• Maple Syrup Urine Disease
• Medium Chain Acyl CoA Dehydrogenase Deficiency
• Malonic Acidemia
• Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
• Isovaleric Acidemia
• Phosphoserine Aminotransferase Deficiency
• Phosphoserine Phosphatase Deficiency
• Hyperornithinemia-Hyperammonemia-Homocitrullinuria
• S-Adenosylhomocysteine Hydrolase Deficiency
• Mucopolysaccharidosis VII
• Mucopolysaccharidosis VI
• Mucopolysaccharidosis IV A
• Mucopolysaccharidosis II
• Mucopolysaccharidosis I
• Transcobalamin Deficiency
• Isolated Methylmalonic Acidemia
• Cobalamin Deficiency
• Homocystinuria
• Holocarboxylase Synthetase Deficiency
• Fanconi Bickel Syndrome
• Glycogen Storage Disease
• Glycine Encephalopathy
• Glutaric Acidemia I
• Glucose Galactose Malabsorption
• Gaucher Disease, Type 1
• Galactosemias
• Fructosemia
• Fructose-1,6-Diphosphatase Deficiency
• Carbamoyl Phosphate Synthase 1 Deficiency
• Citrullinemia Type II
• Citrullinemia 1
• Creatine Deficiency Syndrome
• Systemic Primary Carnitine Deficiency
• Carnitine Palmitoyltransferase Deficiency 2
• Carnitine Palmitoyltransferase Deficiency 1
• Carnitine Acylcarnitine Translocase Deficiency
• Riboflavin Transporter Deficiency
• Branched-Chain Keto Acid Dehydrogenase Kinase Deficiency
• Andersen Tawil Syndrome
• Timothy Syndrome
• Jervell-Lange Nielsen Syndrome
• Catecholaminergic Polymorphic Ventricular Tachycardia
• Familial Hypertrophic Cardiomyopathy Type 4
• Pseudohypoaldosteronism, Type II
• Pseudohypoaldosteronism Type 1
• Primary Hyperoxaluria
• X Linked Hypophosphatemia
• Hereditary Nephrogenic Diabetes Insipidus
• Cystinosis
• Congenital Nephrotic Syndrome, Finnish Type
• Alport Syndrome
• Hereditary Retinoblastoma
• Biotinidase Deficiency
• Aciduria, Argininosuccinic
• Argininemia
• Acyl-CoA Dehydrogenase Family, Member 9, Deficiency of
• 3-Hydroxy 3-Methyl Glutaric Aciduria
• 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 Deficiency

• Intervention: Not Provided

Study Groups/Cohorts

Newborns with consent

Newborns with parent's consent

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: October 24, 2023): 6000
• Original Estimated Enrollment (submitted: January 13, 2023): 40000
• Estimated Study Completion Date: August 31, 2025
• Estimated Primary Completion Date: August 31, 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• newborn between birth and 28 days of life
• consent of parent

Exclusion Criteria:

• + 28 days
• Non consent of parent

Sex/Gender

• Sexes Eligible for Study: All

• Ages: up to 28 Days (Child)
• Accepts Healthy Volunteers: Yes

Contacts

Contact: Tamara Dangouloff; +33662438138; tamara.dangouloff@uliege.be

Contact: François Boemer; +3243667696; F.Boemer@chuliege.be

• Listed Location Countries: Belgium

Administrative Information

• NCT Number: NCT05687474
• Other Study ID Numbers: 2021-239
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Laurent Servais, Centre Hospitalier Universitaire de Liege
• Original Responsible Party: Laurent Servais, Centre Hospitalier Régional de la Citadelle, Professor
• Current Study Sponsor: Centre Hospitalier Universitaire de Liege
• Original Study Sponsor: Laurent Servais

Collaborators

• Centre Hospitalier Régional de la Citadelle
• University of Liege
• Sanofi
• Orchard Therapeutics
• Takeda
• Zentech-Lacar Company
• Leon Fredericq Foundation

Investigators

• Principal Investigator: Laurent Servais; Centre Hospitalier Universitaire de Liege

• PRS Account: Centre Hospitalier Universitaire de Liege
• Verification Date: April 2024